Literature DB >> 32418245

New Guidance on Managing Inpatient Hyperglycaemia during the COVID-19 Pandemic.

G Rayman1, A Lumb2, B Kennon3, C Cottrell4, D Nagi5, E Page1, D Voigt6, H Courtney7, H Atkins8, J Platts9, K Higgins8, K Dhatariya10, M Patel11, P Narendran12, P Kar13, P Newland-Jones14, R Stewart15, O Burr16, S Thomas17.   

Abstract

Entities:  

Mesh：

Year:  2020        PMID： 32418245     DOI： 10.1111/dme.14327

Source DB:  PubMed          Journal:  Diabet Med        ISSN： 0742-3071            Impact factor:   4.359


× No keyword cloud information.
  5 in total

Review 1.  Inpatient Hyperglycemia Management and COVID-19.

Authors:  Virginia Bellido; Antonio Pérez
Journal:  Diabetes Ther       Date:  2020-12-05       Impact factor: 2.945

2.  Diabetes and Covid-19: Clinical implications and novel management strategies.

Authors:  R D'Arcy; C H Courtney
Journal:  Ulster Med J       Date:  2021-07-08

Review 3.  Endocrine and metabolic aspects of the COVID-19 pandemic.

Authors:  Mónica Marazuela; Andrea Giustina; Manuel Puig-Domingo
Journal:  Rev Endocr Metab Disord       Date:  2020-12       Impact factor: 6.514

Review 4.  Impact of diabetes on COVID-19 and other infection: Report from the 22nd Hong Kong Diabetes and Cardiovascular Risk Factors-East Meets West Symposium.

Authors:  Andrea O Y Luk; Susanna S S Ng; Richard I G Holt
Journal:  Diabet Med       Date:  2021-03-02       Impact factor: 4.213

5.  Dexamethasone therapy in COVID-19 patients: implications and guidance for the management of blood glucose in people with and without diabetes.

Authors:  G Rayman; A N Lumb; B Kennon; C Cottrell; D Nagi; E Page; D Voigt; H C Courtney; H Atkins; K Higgins; J Platts; K Dhatariya; M Patel; P Newland-Jones; P Narendran; P Kar; O Burr; S Thomas; R Stewart
Journal:  Diabet Med       Date:  2020-09-21       Impact factor: 4.213
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.